GLMD — Galmed Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $5.75m
- -$13.30m
- 23
- 55
- 49
- 37
Annual balance sheet for Galmed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 50.9 | 34.8 | 13.8 | 12.6 | 15.3 |
| Net Total Receivables | 0.066 | 0.079 | 0.124 | 0.165 | 0.209 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 51.8 | 36.1 | 14.7 | 13.2 | 16.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.57 | 0.551 | 0.337 | 0.125 | 0 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 52.4 | 36.6 | 16.6 | 16.6 | 18.5 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.01 | 5.88 | 3.09 | 2.75 | 2.17 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.23 | 6.11 | 3.14 | 2.75 | 2.17 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 44.2 | 30.5 | 13.4 | 13.9 | 16.3 |
| Total Liabilities & Shareholders' Equity | 52.4 | 36.6 | 16.6 | 16.6 | 18.5 |
| Total Common Shares Outstanding |